Global Oncology Intelligence
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Hospital Solutions
-
Business Intelligence and Data Science
-
Commercial Services for Optimal Performance
-
Commercial Engagement Services
-
Commercial Support Solutions
-
Commercial Technologies
-
Real World Evidence
-
Activation Services
-
Clinical Research & Development Solutions
Hospital Solutions
Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?
OverviewKey Solutions for Hospitals
Business Intelligence and Data Science
As part of the global healthcare community, IQVIA Belgium and its BIDS team (Business Intelligence and Data Science) continuously invest in ways to help life science companies find the next breakthrough in improving human health.
OverviewKey Solutions for Bids
Commercial Services for Optimal Performance
Given the dynamic marketplace, your need to rely on sound information has never been greater. You must make fast decisions without delay. Innovate without undue risk. Execute without faltering.
OverviewKey solutions
Commercial Engagement Services
We can help you get your product to patients quickly. This is done by finding the right candidates to help you in assembling a qualitative team that is trained and equipped with the best tools & applications. With the unique IQVIA approach, we can also make sure you target the right healthcare providers.
OverviewKey solutions
Commercial Support Solutions
IQVIA helps our customers generate real world evidence (RWE) to unlock the value of their investment at every stage of the product life cycle.
OverviewCommercial Technologies
Let yourself be guided and get in direct contact with your key partners in your market. With IQVIA Pharm In Touch, IQVIA Dental In Touch, IQVIA MobiRep and integrated services, you will have even more freedom of movement.
OverviewReal World Evidence
IQVIA helps our customers generate real world evidence (RWE) to unlock the value of their investment at every stage of the product life cycle.
OverviewActivation Services
As the essential partner for pharmacists and pharmaceutical companies we offer effective activation services and marketing tools to meet today's challenges. The Activation Services department of IQVIA is specialised in pharmacy communication and puts its expertise at the service of its partners.
OverviewClinical Research & Development Solutions
Reimagine clinical development by intelligently connecting data, technology and analytics to optimize your trials. The result? Faster decision making, innovation with reduced risk and driving trials without compromise so you can deliver life-changing therapies faster.
OverviewKey solutions
PRODUCTS
-
Pharmaceutical company
Are you a pharmaceuticals ?
IQVIA is a world leader in using data, technology, advanced analytics and human expertise.
OverviewCareers Belgium
Why work at IQVIA Belux? Help create a healthier world—start right here where we offer a diverse selection of opportunities.
Learn moreExplore our Roles
We understand that part of your role involves spending a lot of time on the road, which is why at IQVIA we give you the opportunity to schedule your own agenda.
Learn moreBlog
Empowering Oncology care through advancements, insights, and collaborative solutions
Feb 26, 2025
Empowering Oncology care through advancements, insights, and collaborative solutions
This article is the first in a series of four exploring the future of oncology care. As we look to the future, the hope is that cancer will become a thing of the past, rendering the role of oncologists obsolete. For now, however, cancer continues to pose a formidable global health challenge. The field of cancer treatment is advancing rapidly, with new, sophisticated therapies emerging at an unprecedented pace. This progress requires oncologists to continually expand their knowledge and skills. Selecting the most appropriate treatment from a growing arsenal of options demands expertise in genomics, proteomics, cell biology, and drug toxicity. Additionally, modern cancer care necessitates close collaboration among a diverse team of specialists, including surgeons, radiation oncologists, pathologists, and oncology nurses.
Recent years have seen significant advancements in cancer therapies, increasing the complexity of treatment options and the need for continuous learning among oncologists.
Despite these advancements, cancer remains a leading cause of death and financial burden globally, necessitating innovative solutions and collaborations to improve patient outcomes.
Let’s investigate the key trends and challenges in the oncology market.
Recent oncology market trends:
A total of 115 oncology NASs have launched globally in the past 5 years and 237 over 20 years, with large geographic variations.
Number of oncology novel active substances launched globally and in selected countries, 2003-2022.
- Source: IQVIA Institute – Global Oncology Trends 2023
- China now represents 23% of the global oncology pipeline, surpassing Europe for the first time.
- US: 78 novel active substances (NASs) for oncology launched in the past five years; 189 over the last 20 years.
- EU4+UK: 61 NASs launched in the past five years; 157 over the last 20 years.
- China: 75 NASs launched in the past five years; 121 over the last 20 years.
- Notably, 40 global NASs launched in the last 5 years have not launched in the US, and all but four were first launched in China or Japan, suggesting the emergence of divergent sources and destinations of innovation.
Oncology spending by region, US$Bn
Overall cancer medicine spending is rising globally, creating financial pressure on patients, caregivers and stakeholders.
- As a leading cause of death and disease, not only does cancer take an enormous toll on the health of patients and survivors—it also has a tremendous financial impact.
- Cancer medicine spending rose to $196Bn globally in2022, with 75% focused on the major developed markets (US, UK, EU4, JP)
- The US spending has risen from $58Bn in 2018 to $88Bn in 2022, representing 45% of global spending.
- The global cancer medicine spending is expected to reach $375Bn by 2027.
Source: IQVIA Institute – Global Oncology Trends 2023
Recent statistics highlight similarly rapid advancements in oncology within Europe and Belgium:
- Europe accounts for over 30% of the global oncology drugs market, with a projected compound annual growth rate (CAGR) of 11.7% from 2024 to 2031.1
- In Belgium, the oncology drugs market is forecasted to achieve a revenue of $1.08 billion in 2025, with a CAGR of 6.13% from 2025 to 2029.2
- The European Cancer Information System (ECIS) reports that breast, colorectal, cervical, prostate, lung, and gastric cancers account for 54.2% of all new cancer cases and 50.2% of cancer deaths in the EU.3
Key questions arising from these trends:
- How can we better understand the priorities and perspectives of patients and HCPs in oncology?
- What strategies can be employed to foster deeper collaboration among multidisciplinary teams?
- How can we streamline patient access to treatments and identify key opinion leaders (KOLs) within the oncology field?
Who’s on the cancer patient’s team?
IQVIA's approach to address these challenges
IQVIA emphasizes close collaboration with HCPs to understand their priorities and perspectives.What we do:
- Patient journey mapping and referral pathways
- Patient experience insights
- Identification of multidisciplinary KOLs and influence networks
- HCO mapping to provide a comprehensive understanding of patient and HCP needs
- Streamlining routes to treatment access and identifying referring versus treating centers
- Facilitation of strategic workshops and hospital training programs
We also can support you via digital patient engagement tools, telehealth solutions, and AI-driven insights to optimize oncology outcomes.
This holistic approach helps to position your medicines more effectively within the dynamic of the multidisciplinary patient care framework, ultimately leading to better patient outcomes and stronger HCP relationships.
Addressing key questions in oncology:
We have identified six critical questions shaping oncology care:
-
1. How to prioritize multidisciplinary patient care targets?
2. How to address smaller, biomarker-based patient populations?
3. How does early-stage vs. advanced oncology care differ?
4. How can we accelerate patient access to novel therapies?
5. How can we track market share in combination therapies?
6. How can capacity planning adapt to evolving needs?
For more insights on how we unravel the complexities of cancer treatment with patient-level data-driven solutions, please consult this our oncology intelligence webpage: https://www.iqvia.com/solutions/commercialization/brand-strategy-and-management/global-oncology-intelligence
If you would like to discuss how IQVIA can support your oncology initiatives, please reach out to Sophie.tigranoff@iqvia.com or Kristin.vandendaele@iqvia.com.
1.Europe Oncology Drugs Market Report 2025; 2. Oncology Drugs – Belgium - Statista Market Forecast; 3. 2022 New cancer cases and cancer deaths on the rise in the EU